Economic assessment of early initiation of inhaled corticosteroids in chronic obstructive pulmonary disease using propensity score matching

Clinical Therapeutics

Volumn 30, Issue PART 1, 2008, Pages 1003-1016

  Akazawa, Manabu ^a   Biddle, Andrea K ^a   Stearns, Sally C ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

chronic obstructive pulmonary disease; exacerbation; health expenditure; inhaled corticosteroid; propensity score matching

Indexed keywords

ANTIBIOTIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; THEOPHYLLINE;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE EXACERBATION; DISEASE SEVERITY; ECONOMIC ASPECT; EMERGENCY WARD; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; PHARMACY; RETROSPECTIVE STUDY; SCORING SYSTEM;

ADMINISTRATION, INHALATION; ADULT; AGED; BRONCHODILATOR AGENTS; COHORT STUDIES; COSTS AND COST ANALYSIS; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HEALTH SERVICES; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RETROSPECTIVE STUDIES;

EID: 47149115749     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2008.05.020     Document Type: Article

References (41)

1. Man S., McAlister F., Anthonisen N., and Sinn D. Contemporary management of chronic obstructive pulmonary disease: Clinical applications. JAMA 290 (2003) 2313-2316
2. Mannino D., Watt G., Hole D., et al. The natural history of chronic obstructive pulmonary disease. Eur Respir J 27 (2006) 627-643
3. Mannino D., Homa D., Akinbami L., et al. Chronic obstructive pulmonary disease surveillance-United States, 1971-2000. MMWR Surveill Summ 51 (2002) 1-16
4. NHLBI (National Heart, Lung, and Blood Institute). Morbidity & Mortality: 2007 Chart Book on Cardiovascular, Lung and Blood Diseases (2007), US Dept of Health and Human Services, Public Health Service, National Institutes of Health, Bethesda, Md. http://www.nhlbi.nih.gov/resources/docs/07-chtbk.pdf Accessed April 11, 2008
5. Marton J., Boulanger L., Friedman M., et al. Assessing the costs of chronic obstructive pulmonary disease: The state Medicaid perspective. Respir Med 100 (2006) 996-1005
6. Miller J., Foster T., Boulanger L., et al. Direct costs of COPD in the US: An analysis of Medical Expenditure Panel Survey (MEPS) data. COPD 2 (2005) 311-318
7. GOLD (Global Initiative for Chronic Obstructive Lung Disease). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (December 2007). http://www.goldcopd.org/ Accessed April 11, 2008
8. Sin D., McAlister F., Man S., and Anthonisen N. Contemporary management of chronic obstructive pulmonary disease: Scientific review. JAMA 290 (2003) 2301-2312
9. Calverley P., Anderson J., Celli B., et al., for the TORCH Investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 356 (2007) 775-789
10. Nannini L., Cates C., Lasserson T., and Poole P. Combined corticosteroid and long-acting beta-agonist in one inhaler versus long-acting beta-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. (2007) CD006829
11. Nannini L., Cates C., Lasserson T., and Poole P. Combined corticosteroid and long-acting beta-agonist in one inhaler versus inhaled steroids for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. (2007) CD006826
12. Donaldson G., and Wedzicha J. COPD exacerbations. 1: Epidemiology. Thorax 61 (2006) 164-168
13. Ramsey S., and Sullivan S. The burden of illness and economic evaluation for COPD. Eur Respir J Suppl 41 (2003) 29S-35S
14. Holguin F., Folch E., Redd S., and Mannino D. Comorbidity and mortality in COPD-related hospitalizations in the United States, 1979 to 2001. Chest 128 (2005) 2005-2011
15. Shaya F., El Khoury A., Samant N., and Scharf S. Utilization of health care resources in a high-risk Medic-aid population with chronic obstructive pulmonary disease. P&T 31 (2006) 261-268
16. Schneeweiss S., and Avorn J. A review of uses of health care utilization data-bases for epidemiologic research on therapeutics. J Clin Epidemiol 58 (2005) 323-337
17. IHCIS (Integrated Healthcare Information System). National Managed Care Benchmark Database, User Manual (June 2005), Ingenix (formerly IHCIS), Eden Prairie, Minn
18. D'Agostino Jr. R. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 17 (1998) 2265-2281
19. Joffe M., and Rosenbaum P. Invited commentary: Propensity scores. Am J Epidemiol 150 (1999) 327-333
20. Baser O. Too much ado about propensity score models? Comparing methods of propensity score matching. Value Health 9 (2006) 377-385
21. Mapel D., Dedrick D., and Davis K. Trends and cardiovascular comorbidities of COPD patients in the Veterans Administration Medical System, 1991-1999. COPD 2 (2005) 35-41
22. Soriano J., Visick G., Muellerova H., et al. Patterns of comorbidities in newly diagnosed COPD and asthma in primary care. Chest 128 (2005) 2099-2107
23. Charlson M., Pompei P., Ales K., and MacKenzie C. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 40 (1987) 373-383
24. Deyo R., Cherkin D., and Ciol M. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45 (1992) 613-619
25. Kleinbaum D., Kupper L., Muller K., et al. Applied Regression Analysis and Other Multivariable Methods. 3rd ed (1998), Duxbury Press, Pacific Grove, Calif
26. Allison P. Logistic Regression Using the SAS System (1999), SAS Institute, Cary, NC
27. Blough D., Madden C., and Horn-brook M. Modeling risk using generalized linear models. J Health Econ 18 (1999) 153-171
28. Manning W., and Mullahy J. Estimating log models: To transform or not to transform?. J Health Econ 20 (2001) 461-494
29. Collet J.-P., and Boivin J.-F. Bias and confounding in pharmacoepidemiology. In: Strom B. (Ed). Pharmacoepidemiology. 3rd ed (2000), Wiley & Sons, Ltd, Chichester, UK
30. Burney P., Suissa S., Soriano J., et al. The pharmacoepidemiology of COPD: Recent advances and methodological discussion. Eur Respir J Suppl 43 (2003) 1S-44S
31. Sin D., and Tu J. Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 164 (2001) 580-584
32. Soriano J., Vestbo J., Pride N., et al. Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice. Eur Respir J 20 (2002) 819-825
33. Kiri V., Pride N., Soriano J., and Vestbo J. Inhaled corticosteroids in chronic obstructive pulmonary disease: Results from two observational designs free of immortal time bias. Am J Respir Crit Care Med 172 (2005) 460-464
34. Fan V., Bryson C., Curtis J., et al. Inhaled corticosteroids in chronic obstructive pulmonary disease and risk of death and hospitalization: Time-dependent analysis. Am J Respir Crit Care Med 168 (2003) 1488-1494
35. Suissa S. Effectiveness of inhaled corticosteroids in chronic obstructive pulmonary disease: Immortal time bias in observational studies. Am J Respir Crit Care Med 168 (2003) 49-53
36. Suissa S. Inhaled steroids and mortality in COPD: Bias from unaccounted immortal time. Eur Respir J 23 (2004) 391-395
37. Rothman K., and Greenland S. Modern Epidemiology. 2nd ed (1998), Lippincott-Raven, Philadelphia, Pa
38. Rascati K., Akazawa M., Johnsrud M., et al. Comparison of hospitalizations, emergency department visits, and costs in a historical cohort of Texas Medicaid patients with chronic obstructive pulmonary disease, by initial medication regimen. Clin Ther 29 (2007) 1203-1213
39. Global Strategy for Asthma Management and Prevention (2006) [GINA Global Initiative for Asthma Web site]
40. http://www.ginasthma.org Accessed March 12, 2007
41. Stürmer T., Joshi M., Glynn R., et al. A review of the application of pro-pensity score methods yielded increasing use, advantages in specific settings, but not substantially dif-ferent estimates compared with conventional multivariable methods. J Clin Epidemiol 59 (2006) 437-447